Cerevance, a Boston, Massachusetts and Cambridge, UK-based drug discovery startup, raised $5m in equity funding.
The Dementia Discovery Fund, a fund managed by SV Life Sciences, made the investment. In conjunction with the funding, Tetsuyuki Maruyama, Ph.D., Chief Scientific Officer of the Dementia Discovery Fund, will join Cerevance’s Board of Directors.
Together with the $36m in commitments of equity and non-dilutive capital from Lightstone Ventures and Takeda Pharmaceuticals Company, Ltd. (TSE: 4502) announced in December, the new company has now raised over $41m.
Led by Brad Margus, Chief Executive Officer, Cerevance leverages a proprietary technology platform, invented in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D. at Rockefeller University, to enable the molecular analysis of specific cell types in human brain tissue to reveal critical pathways and receptors present in vulnerable cell populations as well as molecular responses in those cell populations to diseases such as Alzheimer’s and Parkinson’s disease.